Related Experiment Video
Updated: Jul 17, 2026

Workflow and Framework for Collecting and Implementing Point-of-Care Ultrasound Data in the Management of Heart Failure Patients
Published on: July 12, 2024
Managing congestive heart failure in a general hospital in Malaysia. Are we keeping pace with evidence?
Insights
Evidence-based heart failure treatments like ACE-inhibitors and diuretics are underused in acute and chronic heart failure patients. Barriers include limited experience and funding for newer drugs like spironolactone and beta-blockers.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Current heart failure management guidelines recommend beta-blockers and spironolactone alongside diuretics and ACE inhibitors.
- The study investigates the practical application of these evidence-based recommendations.
Purpose of the Study:
- To assess the adherence to heart failure management guidelines in acute and chronic stable heart failure patients.
- To identify challenges in implementing recommended therapies.
Main Methods:
- Retrospective analysis of 80 hospitalized patients with acute decompensated heart failure and 74 chronic stable heart failure outpatients.
- Data collected at admission, discharge, and 12-week follow-up for acute HF patients.
- Comparison of medication prescriptions and clinic attendance rates.
Main Results:
- Less than half of patients with left ventricular dysfunction were on ACE inhibitors (47%) or diuretics (39%) prior to hospitalization.
- All acute HF patients received diuretics and ACE inhibitors during hospitalization.
- Medication prescription rates for diuretics and ACE inhibitors decreased at 12 weeks post-discharge but remained higher than in chronic HF patients.
- Spironolactone and beta-blocker use was limited due to lack of experience and funding.
- Clinic non-attendance was significant, attributed to patient-related factors.
Conclusions:
- Diuretics and ACE inhibitors are underutilized in recurrent heart failure management.
- Implementation of spironolactone and beta-blockers is slow, hindered by medical experience and financial constraints.
- Patient factors contribute to significant clinic non-attendance, impacting follow-up care.
Abstract:
Evidence-based heart failure management now includes beta-blockers and spironolactone in addition to diuretics and angiotensin-converting enzyme inhibitors. We aim to determine if these recommendations had been applied in practice for acute and chronic stable heart failure, and what difficulties there might be. Data from 80 consecutive patients hospitalized for decompensated heart failure ('acute') between May and July 2003 were analyzed at admission, upon discharge and at 12 weeks follow-up; along with 74 cardiology clinic out-patients with stable congestive heart failure ('chronic'- no decompensation or admission in previous six months). Less than half of study patients with prior left ventricular dysfunction were on ACE-inhibitors (47%), diuretics (39%), ATII antagonists, spironolactone or digoxin (5% each). All 'acute' patients were commenced on diuretics and ACE-inhibitors in hospital. Six patients died or transferred to another center. Compliance with clinic appointment at 12 weeks was 85% despite telephone reminders. Drug prescription at 12 weeks was significantly lower for diuretics and ACE-inhibitors compared to prescription at discharge (all p < 0.05) but higher compared to patients with chronic HF. Diuretics and ACE inhibitors remain under-utilized for patients with recurrent heart failure. Use of spironolactone and beta-blocker is slow due to limited medical experience and funding. Clinic non-attendance is significant and due to patient factors.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Rheumatic Heart Disease III: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care